FDA Grants Priority Review to Tebentafusp for Uveal Melanoma Treatment
Source: Targeted Oncology, August 2021
The FDA has accepted the biologics license application (BLA) for tebentafusp (IMCgp100) and granted it priority review for the treatment of adult patients with HLA-A*02:01-positive metastatic uveal melanoma (mUM), according to a press release by Immunocore Holdings Plc.1
